Cargando…
Cardiovascular effects of rivaroxaban in heart failure patients with sinus rhythm and coronary disease with and without diabetes: a retrospective international cohort study from COMMANDER-HF
OBJECTIVES: COMMANDER-HF was a randomised trial comparing rivaroxaban 2.5 mg two times a day to placebo, in addition to antiplatelet therapy, in patients hospitalised for worsening heart failure with coronary artery disease and sinus rhythm. Patients with diabetes are at increased risk of cardiovasc...
Autores principales: | Sharma, Abhinav, Caldeira, Daniel, Razaghizad, Amir, Pinto, Fausto J, van Veldhuisen, Dirk J, Mehra, Mandeep R, Lam, Carolyn S P, Cleland, John, Anker, Stefan D, Greenberg, Barry, Ferreira, Joao Pedro, Zannad, Faiez |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10423780/ https://www.ncbi.nlm.nih.gov/pubmed/37567750 http://dx.doi.org/10.1136/bmjopen-2022-068865 |
Ejemplares similares
-
A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trial
por: Mehra, Mandeep R, et al.
Publicado: (2019) -
Rationale and design of a randomized, double‐blind, event‐driven, multicentre study comparing the efficacy and safety of oral rivaroxaban with placebo for reducing the risk of death, myocardial infarction or stroke in subjects with heart failure and significant coronary artery disease following an exacerbation of heart failure: the COMMANDER HF trial
por: Zannad, Faiez, et al.
Publicado: (2015) -
Inflammation and remodeling pathways and risk of cardiovascular events in patients with ischemic heart failure and reduced ejection fraction
por: Girerd, Nicolas, et al.
Publicado: (2022) -
Metabolic Syndrome and the Risk of Preclinical Heart Failure: Insights after 17 Years of Follow-Up from the STANISLAS Cohort
por: Sharma, Abhinav, et al.
Publicado: (2022) -
Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial
por: Pitt, Bertram, et al.
Publicado: (2011)